Shares of Allergan jumped 2.2 percent Wednesday after analysts at Morgan Stanley downplayed concern over competitive pressure for its key product, Botox. "Fears about a 'better Botox' may be overdone," said analyst David Risinger in a note to clients. He noted that it "could be difficult" for competitor Revance Therapeutics to show that its Botox-like product, botulinum toxin RT002, "is materially longer-lasting than Botox, which has been a concern for AGN investors." Allergan shares are down 23 percent over the past three months, while Revance's stock is up 7.4 percent in that time period.